Two people with advanced cancer remain on a trial drug for over 500 days, with stable disease.

Pasithea Therapeutics (KTTA) reported Phase 1 trial data for PAS-004, an oral MEK inhibitor, showing stable disease in advanced solid tumor patients. Four patients remained on treatment for over 300 days, with two over 500 days. No dose-limiting toxicities were observed. The data was presented at ESMO Congress 2026.

Pasithea reported Phase 1 data for PAS-004, showing stable disease in 4 advanced cancer patients, with no serious adverse events. The company noted no dose-limiting toxicities and supports daily dosing. The data is preliminary and requires further Phase 2 studies for validation.

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

Genmab A/S (GMAB) reported that its phase 3 trial of rinatabart sesutecan met primary and key secondary endpoints in platinum-resistant ovarian cancer. The drug showed a 71% reduction in disease progression or death risk vs. chemotherapy. Genmab plans regulatory discussions and future data presentations.

Genmab reported positive Phase 3 results for Rina-S in ovarian cancer, showing 71% reduction in PFS risk and 57% reduction in OS risk. The company plans regulatory discussions. According to the company, safety data was consistent with previous studies.

Moderna (MRNA) fell 17% after phase 3 data for its cancer vaccine showed less improvement than expected. Analysts are divided on its potential, with some citing concerns over efficacy, cost, and complexity. Merck's (MRK) Keytruda was part of the trial.